JULIAN A KIM, MD
Radiology at Euclid Ave, Cleveland, OH
License number
Ohio 35-065604
Category
Radiology
Type
Surgery
Address
Address
11100 Euclid Ave, Cleveland, OH 44106
Phone
(216) 844-7874
Personal information
See more information about JULIAN A KIM at radaris.comName
Address
Phone
536 Slate Ln, Blacklick, OH 43004
2380 Hardesty Ct, Columbus, OH 43204
21899 Parnell Rd, Shaker Heights, OH 44122
Beachwood, OH
410 10Th Ave, Columbus, OH 43210
Organization information
See more information about JULIAN A KIM at bizstanding.comJulian Kim MD
11100 Euclid Ave, Cleveland, OH 44106
Industry:
Surgeons, Oncology, Emergency Medicine
Site:
Phone:
(216) 844-7874 (Phone)
Description:
There are 3 doctors at this site. Surgery is performed at this site.
Julian Anthony Kim
Professional information
See more information about JULIAN A KIM at trustoria.com
Julian A Kim, Cleveland OH
Julian A Kim, Cleveland OH
Specialties:
Surgeon
Address:
9500 Euclid Ave, Cleveland, OH 44195
11100 Euclid Ave, Cleveland, OH 44106
11100 Euclid Ave, Cleveland, OH 44106
Board certifications:
American Board of Surgery Certification in Surgery
Julian Kim, Cleveland OH
Julian Kim, Cleveland OH
Specialties:
Surgery, Surgical Oncology
Work:
Uh Seidman Cancer Center
11100 Euclid Ave, Cleveland, OH 44106
11100 Euclid Ave, Cleveland, OH 44106
Education:
The University of Toledo (1986)
Julian Anthony Kim, Cleveland OH
Julian Anthony Kim, Cleveland OH
Specialties:
Emergency Medicine, Surgery, Surgical Oncology
Work:
University Hospitals Case Medical Center
11100 Euclid Ave, Cleveland, OH 44106
11100 Euclid Ave, Cleveland, OH 44106
Education:
Medical College of Ohio (1986)
Nucleic Acid-Mediated Treatment Of Diseases Or Conditions Related To Levels Of Vascular Endothelial Growth Factor Receptor (Vegf-R)
Nucleic Acid-Mediated Treatment Of Diseases Or Conditions Related To Levels Of Vascular Endothelial Growth Factor Receptor (Vegf-R)
US Patent:
2004010, May 27, 2004
Filed:
Nov 4, 2002
Appl. No.:
10/287949
Inventors:
Pamela Pavco - Lafayette CO, US
James McSwiggen - Boulder CO, US
Dan Stinchcomb - Ft. Collins CO, US
Jaime Escobedo - Alamo CA, US
Julian Kim - Shaker Heights OH, US
Daniel Lindner - Shaker Heights OH, US
James McSwiggen - Boulder CO, US
Dan Stinchcomb - Ft. Collins CO, US
Jaime Escobedo - Alamo CA, US
Julian Kim - Shaker Heights OH, US
Daniel Lindner - Shaker Heights OH, US
Assignee:
Ribozyme Pharmaceuticals, Inc.
International Classification:
A61K048/00, C12N005/08
US Classification:
514/044000, 435/372000, 435/375000
Abstract:
The present invention relates to nucleic acid molecules such as ribozymes, DNAzymes, short interfering RNA (siRNA), short interfering nuleic acid (siNA), and antisense which modulate the synthesis, expression and/or stability of an mRNA encoding one or more receptors of vascular endothelial growth factor, such as flt-1 (VEGFR1) and/or KDR (VEGFR2). Nucleic acid molecules and methods for the inhibition of angiogenesis and treatment of cancer and other conditions associated with VEGF-R are provided, optionally in conjunction with other therapeutic agents such as interferons.
Nucleic Acid-Mediated Treatment Of Diseases Or Conditions Related To Levels Of Vascular Endothelial Growth Factor Receptor (Vegf-R)
Nucleic Acid-Mediated Treatment Of Diseases Or Conditions Related To Levels Of Vascular Endothelial Growth Factor Receptor (Vegf-R)
US Patent:
2009017, Jul 2, 2009
Filed:
Jul 9, 2008
Appl. No.:
12/170393
Inventors:
Pamela Pavco - Lafayette CO, US
James McSwiggen - Boulder CO, US
Dan Stinchcomb - Ft. Collins CO, US
Jaime Escobedo - Alamo CA, US
Julian Kim - Shaker Heights OH, US
Daniel Lindner - Shaker Heights OH, US
James McSwiggen - Boulder CO, US
Dan Stinchcomb - Ft. Collins CO, US
Jaime Escobedo - Alamo CA, US
Julian Kim - Shaker Heights OH, US
Daniel Lindner - Shaker Heights OH, US
Assignee:
SIRNA THERAPEUTICS INC. - San Francisco CA
International Classification:
C12N 5/08, C12N 5/06
US Classification:
435377
Abstract:
The present invention relates to nucleic acid molecules such as ribozymes, DNAzymes, short interfering RNA (siRNA), short interfering nucleic acid (siNA), and antisense which modulate the synthesis, expression and/or stability of an mRNA encoding one or more receptors of vascular endothelial growth factor, such as flt-1 (VEGFR1) and/or KDR (VEGFR2). Nucleic acid molecules and methods for the inhibition of angiogenesis and treatment of cancer and other conditions associated with VEGF-R are provided, optionally in conjunction with other therapeutic agents such as interferons.